Prevalence and Clinical Severity of Autoimmune Blistering Diseases
University of Pennsylvania
Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Description
The disease severity instruments for pemphigus and BP, the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), respectively, have the potential to capture changes in all grades of disease activity, including mild disease, and therefore represent a substantial improvement over simple lesion counts or measurements of affected body surface area. However, full validation of the PDAI and BPDAI for use in clinical trials will require additional and more extensive measurements that will enable us to classify patients correctly by disease severity and be able to…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons
Interventions
- OtherQuestionnaires
Locations (3)
- Hospital of the University of Pennsylvania, Department of DermatologyPhiladelphia, Pennsylvania
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
- University of Pennsylvania, Department of DermatologyPhiladelphia, Pennsylvania